Navigation Links
Mayo Clinic News Release: Mayo Clinic-led Study Improves Breast,Cancer Risk Prediction in Women with Atypia

and Carol Reynolds, M.D. Collaborators from other institutions included Daniel Visscher, M.D., University of Michigan; Hal Berman, M.D. and Thea Tlsty, Ph.D., University of California, San Francisco; and Thomas Sellers, M.D., Ph.D., H. Lee Moffitt Cancer and Research Institute, Tampa, Fla.

The research was supported in part by a Department of Defense Center of Excellence Grant, the Susan G. Komen Breast Cancer Foundation, the Breast Cancer Research Foundation, and the Fred C. and Katherine B. Andersen Foundation. For more information about breast cancer and other research at Mayo Clinic Cancer Center, visit the Web site at http://cancercenter.mayo.edu. http://www.mayoclinic.org/news2007-rst/4117.html?src=email-release To obtain the latest news releases from Mayo Clinic, go to http://www.mayoclinic.org/news/. MayoClinic.com (http://www.mayoclinic.com) is available as a resource for your health stories.


'"/>




Page: 1 2 3

Related medicine technology :

1. Genetic Analysis Systems Enter the Clinical Mainstream
2. Clinical Study Shows Regenecare Relieves Pain and Itching of Skin Rashes Caused by Widely Used Cancer Drugs
3. Large Geographic Differences in EpiPen Prescriptions in the U.S., From the Journal of Allergy and Clinical Immunology
4. Clinical Data Suggest Decreased Bleeding Risk in People With Severe Hemophilia A While Maintaining Factor VIII Levels Above One Percent
5. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
6. Halozyme Therapeutics Enhanze Technology Large Protein Molecule Therapeutic Clinical Trial Results Presented at the 34th Annual Meeting of the Controlled Release Society
7. Corgenix Reports New Clinical Data Correlating AtherOx Technology With Vascular Disease
8. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
9. Protox Announces Positive Clinical Data from Prostate Cancer Study
10. AM-Pharma Announces Positive Results of Phase IIa Clinical Trial with Alkaline Phosphatase For Ulcerative Colitis
11. Cougar Biotechnology Announces Presentation of Positive CB7630 Clinical Data at ESMO Conference
Post Your Comments:
(Date:10/13/2008)...ave Higher Sensitivity and Specificity, than Othe...he preferred test in all phases of...- AT First Diagnostic LLC an,emerging...st kits, today,announced that a recent evaluation ...earch of the FirstVue(TM) HBSAG Test, was released...
(Date:10/13/2008)...tiple Cancer Populations Facilitates ...Oct. 13 /- Rubicon Genomics, Inc. tod...mplify DNA samples for The,Cancer Atlas Genome Pro...nd standardize total genomic,DNA from 3,000 tissue...on,GenomePlex(TM) Whole Genome Amplification techn...
(Date:10/12/2008)...in Combination with Chemotherapy, FREMONT, Calif....c., a,development-stage pharmaceutical company dis...Ai)-based therapeutics, today announced that the,j...cy of siRNA targeting,its proprietary target gene ...edition dated October 1, 2008. The paper, entitled...
(Date:10/12/2008)...t. 12 /- Boston,Scientific ...from an analysis,of nearly 7,500 patients from its...ed to confirm the performance of the TAXUS(R) Expr...in real-world practice. The,two-year pooled ARRIVE...,restenosis in patients with diabetes as effective...
Breaking Medicine Technology:Walter Reed Evaluation Concludes FirstVue(TM) HBSAG Test is Preferred over Other Rapid Tests 2Walter Reed Evaluation Concludes FirstVue(TM) HBSAG Test is Preferred over Other Rapid Tests 3Walter Reed Evaluation Concludes FirstVue(TM) HBSAG Test is Preferred over Other Rapid Tests 4Rubicon Provides Genome Amplification for the Cancer Genome Atlas Project 2Rubicon Provides Genome Amplification for the Cancer Genome Atlas Project 3Quark Pharmaceuticals Announces Publication of Study on Use of siRNA against Proprietary Target for Inhibiting Tumor Growth and Sensitization of Cancer Cells to Chemotherapy 2Quark Pharmaceuticals Announces Publication of Study on Use of siRNA against Proprietary Target for Inhibiting Tumor Growth and Sensitization of Cancer Cells to Chemotherapy 3Quark Pharmaceuticals Announces Publication of Study on Use of siRNA against Proprietary Target for Inhibiting Tumor Growth and Sensitization of Cancer Cells to Chemotherapy 4TAXUS(R) Express(R) Stent Shows Similarly Low Re-Intervention Rates in Patients With Diabetes Compared to Non-Diabetics in Arrive Registry Program 2TAXUS(R) Express(R) Stent Shows Similarly Low Re-Intervention Rates in Patients With Diabetes Compared to Non-Diabetics in Arrive Registry Program 3TAXUS(R) Express(R) Stent Shows Similarly Low Re-Intervention Rates in Patients With Diabetes Compared to Non-Diabetics in Arrive Registry Program 4TAXUS(R) Express(R) Stent Shows Similarly Low Re-Intervention Rates in Patients With Diabetes Compared to Non-Diabetics in Arrive Registry Program 5Patti LaBelle Wows Crowd at 5th Annual Lupus Foundation of America Awards Gala 18813 1Patti LaBelle Wows Crowd at 5th Annual Lupus Foundation of America Awards Gala 18813 2Patti LaBelle Wows Crowd at 5th Annual Lupus Foundation of America Awards Gala 18813 3Previously unseen switch regulates breast cancer response to estrogen 18812 1Previously unseen switch regulates breast cancer response to estrogen 18812 2Phase III pivotal results presented of VYVANSE to treat ADHD in adults 18811 1Phase III pivotal results presented of VYVANSE to treat ADHD in adults 18811 2Omron Makes Blood Pressure Monitoring Easy for Women at Any Stage of Life Including Pregnancy 18807 1Omron Makes Blood Pressure Monitoring Easy for Women at Any Stage of Life Including Pregnancy 18807 2Omron Makes Blood Pressure Monitoring Easy for Women at Any Stage of Life Including Pregnancy 18807 3
...ically meaningful pain relief within 5,minutes of ... June 2007 - Archimedes Pharma Ltd,("Archimedes"),...y,presented new clinical data from a Phase II stud...nasal spray aimed at providing a,fast, effective a...in. Data were presented at the 10th Congress of th...
...ating zonisamide SR as a novel component in,EMPATI... 2007 /PRNewswire-FirstCall/ -- Orexigen(TM),Thera...d on the,treatment of central nervous system disor...nced results from a Phase I trial evaluating,safet...sustained-release (SR) formulation of zonisamide. ...
Other Medicine Technology:Archimedes Pharma Presents Positive Efficacy and Safety Data on,Nasalfent at European Association for Palliative Care Congress 2Archimedes Pharma Presents Positive Efficacy and Safety Data on,Nasalfent at European Association for Palliative Care Congress 3OREXIGEN Therapeutics Announces Sustained-Release Formulation of,Zonisamide Shows Improved Tolerability When Compared to Immediate,Release Formulation 2OREXIGEN Therapeutics Announces Sustained-Release Formulation of,Zonisamide Shows Improved Tolerability When Compared to Immediate,Release Formulation 3OREXIGEN Therapeutics Announces Sustained-Release Formulation of,Zonisamide Shows Improved Tolerability When Compared to Immediate,Release Formulation 4
(Date:10/13/2008)...eading Content Rights Management System, Supports... Content Spend, WEST CHESTER, Pa., Oct. 13 /PRNew...ding global pharmaceutical manufacturer has integr...primary platform for the,secure distribution, data...cs for their new product video content. Imperium i...
(Date:10/13/2008)...swire/ -- The National Coalition for,Quality Color...ncerns over,the National CT Colonography Study pub...Medicine. The evidence must be closely evaluated, ...y is not without significant,potential risks. The ...py,remains the "Gold Standard" for colorectal canc...
(Date:10/13/2008)...blem in daily life, survey shows, PORTLAND, Ore.,...three-quarters of people living with psoriasis say...e, according to a National Psoriasis,Foundation 20...viduals with psoriasis and psoriatic arthritis,als...ly lives, shapes their,feelings about themselves a...
(Date:10/13/2008)...swire/ -- During the Pri-Med New York,conference a...are providers,took a 20-question quiz prepared by ...n Somerset, NJ. The quiz tested basic knowledge of..., EMR software, and healthcare,administration., T... The average number,of correct answers was only 7....
Breaking Medicine News(10 mins):Health News:Global Pharma Integrates Imperium(TM) to Support Launch Content ROI Initiatives! 2Health News:National Coalition for Quality Colorectal Cancer Screening and Care Conveys Concerns over CT Colonography 2Health News:National Coalition for Quality Colorectal Cancer Screening and Care Conveys Concerns over CT Colonography 3Health News:National Psoriasis Foundation Releases 2008 Study Results 2Health News:MTBC Practice Management Quiz Sends Message to Doctors: There is Real Room for Improvement or a Need to Outsource 2
... of Indian MPs has come together to launch a fight...have planned to start a massive awareness drive an...i-TB drug. It is stated that at least two people d...ee minutes. Around 20 MPs have decided to form ...
...sts linked with Harvard Medical School claim the d... breast tumors from malignant ones.// Harvard’s K...p that participated in the research, described det...33rd national meeting of the American Chemical soc...
...ng to a series of papers published in The Lancet o...nagers is less healthy when compared to their pare...lio and tuberculosis have given way to venereal di...drug abuse etc. The only silver lining to this iss...
...d families of persons infected with deadly viruses...w get a chance to understand how. // An independe...ting of these deadly infections by almost 2000 hem..., in what is acknowledged as the biggest treatment...
Other Medicine News:Health News:Indian Parliamentarians Join to Fight Against TB 2Health News:Detection of Malignant Breast Tumors Made Simpler and More Effective 2Health News:Inquiry into Past NHS Treatment Disaster 2
Gentamicin Reagent Solution (10 mg/ml) liquid
LB Agar plates with 0.1mM EDTA.
Luria bertani broth: 1.0% Tryptone, 0.5% Yeast Extract, 1.0% Sodium Chloride.
2.5% Soytone, 4.8% Yeast Extract, 0.025% Magnesium Sulfate, 130mM Calcium Chloride.
Medicine Products: